The deubiquitinating enzyme Cezanne stabilizes BRCA1 by counteracting APC/C and Ube2S-dependent Lys11-linked ubiquitination

The breast and ovarian tumor suppressor BRCA1 is a cell cycle-regulated protein and tumors with reduced BRCA1 protein level may share molecular features of BRCA1-mutant tumor and respond to PARPi therapy. Here, we identify that BRCA1 protein stability is controlled through ubiquitin lysine 11 (K11)-linkage modification under the regulation of Cezanne deubiquitinating enzyme, APC/C E3 ligase, and Ube2S E2 conjugating enzyme in a cell cycle-dependent manner. Cezanne-deficiency leads to increased BRCA1 K11-ubiquitination, decreased BRCA1 protein level, and increased cellular sensitivity to PARPi. The BRCA1 K11-linked ubiquitination is carried out through a degron on BRCA1 that is recognized by APC/C cofactor Cdh1. Tumor expression and mutational analyses indicate that Cezanne low or Ube2S high expression is associated with "BRCAness" and correlated with poor prognosis in breast cancer patients. Thus, our study has demonstrated a ubiquitin K11-linked ubiquitination pathway that regulates BRCA1 protein stability, dysregulation of which predicts BRCA1-deficiency that may be effectively targeted with PARPi therapy.

• Publication year

  2025

• Venue

  PLoS Biology

• Publication date

  2025-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1371/journal.pbio.3003545PMID 41359628PMCID 12685207
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A transcription‐independent mechanism determines rapid periodic fluctuations of BRCA1 expression

  2023cited by this paper
• DNA repair function scores for 2172 variants in the BRCA1 amino-terminus

  2023cited by this paper
• Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer

  2021cited by this paper
• PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers

  2019cited by this paper
• Crosstalk between Lys63- and Lys11-polyubiquitin signaling at DNA damage sites is driven by Cezanne

  2019influential reference
• An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics

  2018cited by this paper
• Cezanne/OTUD7B is a cell cycle‐regulated deubiquitinase that antagonizes the degradation of APC/C substrates

  2018cited by this paper
• Who guards the guardian? Mechanisms that restrain APC/C during the cell cycle.

  2018cited by this paper
• A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer

  2017cited by this paper
• PARP inhibitors: Synthetic lethality in the clinic

  2017cited by this paper
• mSignatureDB: a database for deciphering mutational signatures in human cancers

  2017cited by this paper
• RNF8- and Ube2S-Dependent Ubiquitin Lysine 11-Linkage Modification in Response to DNA Damage.

  2017influential reference
• TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling

  2017cited by this paper
• Building a Regulatory Network with Short Linear Sequence Motifs: Lessons from the Degrons of the Anaphase-Promoting Complex.

  2016cited by this paper
• BRCAness revisited

  2016cited by this paper
• Molecular basis of Lys11-polyubiquitin specificity in the deubiquitinase Cezanne

  2016cited by this paper
• Structure of BRCA1-BRCT/Abraxas Complex Reveals Phosphorylation-Dependent BRCT Dimerization at DNA Damage Sites

  2016cited by this paper
• Landscape of somatic mutations in 560 breast cancer whole genome sequences

  2016cited by this paper
• Spatiotemporal regulation of the anaphase-promoting complex in mitosis

  2015cited by this paper
• Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia

  2014cited by this paper
• HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.

  2014cited by this paper
• HUWE1 interacts with BRCA1 and promotes its degradation in the ubiquitin-proteasome pathway.

  2014cited by this paper
• Physiological modulation of endogenous BRCA1 p220 abundance suppresses DNA damage during the cell cycle

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• OTU Deubiquitinases Reveal Mechanisms of Linkage Specificity and Enable Ubiquitin Chain Restriction Analysis

  2013cited by this paper
• A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice.

  2013cited by this paper
• Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer

  2013cited by this paper
• Repair of strand breaks by homologous recombination.

  2013cited by this paper
• Push back to respond better: regulatory inhibition of the DNA double-strand break response

  2013cited by this paper
• The F-box Protein FBXO44 Mediates BRCA1 Ubiquitination and Degradation*

  2012cited by this paper
• Pathologic Features and Immunophenotype of Estrogen Receptor–positive Breast Cancers in BRCA1 Mutation Carriers

  2012cited by this paper
• The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity

  2012cited by this paper
• NBA1/MERIT40 and BRE Interaction Is Required for the Integrity of Two Distinct Deubiquitinating Enzyme BRCC36-containing Complexes*

  2011cited by this paper
• The mechanism of linkage-specific ubiquitin chain elongation by a single-subunit E2.

  2011cited by this paper
• Lys11-linked ubiquitin chains adopt compact conformations and are preferentially hydrolyzed by the deubiquitinase Cezanne

  2010cited by this paper
• HERC2 is an E3 ligase that targets BRCA1 for degradation.

  2010cited by this paper
• Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

  2010cited by this paper
• UBE2S drives elongation of K11-linked ubiquitin chains by the Anaphase-Promoting Complex

  2010cited by this paper
• Assembly of k11-linked ubiquitin chains by the anaphase-promoting complex.

  2010influential reference
• Gene expression profile of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer.

  2010cited by this paper
• Identification of a physiological E2 module for the human anaphase-promoting complex

  2009cited by this paper
• Breaking the chains: structure and function of the deubiquitinases

  2009cited by this paper
• UBE2S elongates ubiquitin chains on APC/C substrates to promote mitotic exit

  2009cited by this paper
• NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control.

  2009cited by this paper
• Mechanism of ubiquitin-chain formation by the human anaphase-promoting complex.

  2008cited by this paper
• NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling.

  2008cited by this paper
• Ubiquitin-Binding Protein RAP80 Mediates BRCA1-Dependent DNA Damage Response

  2007cited by this paper
• RAP80 Targets BRCA1 to Specific Ubiquitin Structures at DNA Damage Sites

  2007cited by this paper
• Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage

  2007cited by this paper
• Abraxas and RAP80 Form a BRCA1 Protein Complex Required for the DNA Damage Response

  2007cited by this paper
• The anaphase promoting complex/cyclosome: a machine designed to destroy

  2006influential reference
• Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

  2005cited by this paper
• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  2005cited by this paper
• PLOS Biology

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• Ubiquitination and Proteasomal Degradation of the BRCA1 Tumor Suppressor Is Regulated during Cell Cycle Progression*

  2004cited by this paper
• Epigenetic factors controlling the BRCA1 and BRCA2 genes in sporadic ovarian cancer.

  2002cited by this paper
• The anaphase-promoting complex: it's not just for mitosis any more.

  2002cited by this paper
• December 8

  2001cited by this paper
• The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation*

  2001cited by this paper
• The KEN box: an APC recognition signal distinct from the D box targeted by Cdh1.

  2000cited by this paper
• Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers

  2000cited by this paper
• Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases.

  1999cited by this paper
• Methylation of the BRCA1 promoter region in sporadic breast and ovarian cancer: correlation with disease characteristics

  1999cited by this paper
• BRCA1 is a cell cycle-regulated nuclear phosphoprotein.

  1997cited by this paper
• Novel Multiubiquitin Chain Linkages Catalyzed by the Conjugating Enzymes E2EPF and RAD6 Are Recognized by 26 S Proteasome Subunit 5 (*)

  1996cited by this paper
• Identification of a RING protein that can interact in vivo with the BRCA1 gene product

  1996cited by this paper
• Cell cycle regulation of BRCA1 messenger RNA in human breast epithelial cells.

  1996influential reference
• BRCA1 expression is induced before DNA synthesis in both normal and tumor-derived breast cells.

  1996influential reference
• Cyclin is degraded by the ubiquitin pathway

  1991cited by this paper

• No citing papers are available for this paper.